18 Analysts Have This to Say About Pfizer
Portfolio Pulse from Benzinga Insights
Pfizer (NYSE:PFE) has received various analyst ratings over the last quarter, with 3 bullish, 6 somewhat bullish, 9 indifferent, and no bearish ratings. The average price target for Pfizer is $48.33, which is significantly higher than its current price of $29.8, suggesting a substantial upside. This target has increased by 18.6% over the past month. Analysts typically review stocks quarterly, considering financial statements, meetings, and insider information to provide these ratings.
November 20, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer has been rated positively by analysts, with an average price target of $48.33, indicating a potential upside from the current price of $29.8. The target has risen by 18.6% in the past month.
The unanimous absence of bearish ratings and the substantial increase in the average price target suggest a strong positive sentiment among analysts towards Pfizer. This consensus could lead to increased investor confidence and a potential short-term rise in Pfizer's stock price. However, as analyst ratings are opinions and not guarantees, the importance is not at the maximum level.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100